MiNK Therapeutics, Inc. (Nasdaq: INKT) announced on September 30, 2025 that Colonel (Ret.) John B. Holcomb, MD, FACS, will join the company’s Board of Directors. The appointment was announced today and follows the recent addition of pulmonary critical‑care expert Dr. Terese Hammond to the board.
Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design, and has authored more than 780 peer‑reviewed publications. His expertise in immune activation and clinical trial execution aligns closely with MiNK’s goal of advancing iNKT cell therapies for conditions such as ARDS, graft‑versus‑host disease, and multi‑drug‑resistant infections.
The company’s president and CEO, Jennifer Buell, emphasized that Dr. Holcomb’s experience will help guide MiNK toward its next phase of growth, preparedness, and impact. “John’s perspective will be instrumental in guiding MiNK toward its next phase of growth, preparedness, and impact,” Buell said. The appointment reinforces MiNK’s commitment to clinical rigor and operational excellence as it scales its therapeutic pipeline and global footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.